These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27624575)

  • 1. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.
    Linker RA; Wendt G
    Neurol Ther; 2016 Dec; 5(2):193-201. PubMed ID: 27624575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose-Possible Predictors of Cardiac Outcomes.
    Limmroth V; Ziemssen T; Kleiter I; Wagner B; Schmidt S; Lassek C; Baier-Ebert M; Wendt G; Dechend R; Haverkamp W
    Front Neurol; 2020; 11():818. PubMed ID: 32903376
    [No Abstract]   [Full Text] [Related]  

  • 3. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
    BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
    DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
    Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
    Bermel RA; Hashmonay R; Meng X; Randhawa S; von Rosenstiel P; Sfikas N; Kantor D
    Mult Scler Relat Disord; 2015 May; 4(3):273-80. PubMed ID: 26008945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod (Gilenya
    Pilote S; Simard C; Drolet B
    Fundam Clin Pharmacol; 2017 Aug; 31(4):392-402. PubMed ID: 28299825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.
    Gunay-Polatkan S; Gullu G; Sigirli D; Koc ER; Aydinlar A; Turan OF
    Mult Scler Relat Disord; 2023 Aug; 76():104827. PubMed ID: 37331085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.
    Schurmann P; Basra S; Awar OG; Aguilar D; Basant A; Dragan E; Hutton GJ; Birnbaum Y
    Mult Scler Relat Disord; 2014 May; 3(3):408-12. PubMed ID: 25876482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
    Petruzzo M; Lanzillo R
    Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.